Key Takeaways
Extended Takeaways
- In this sample, treatment engagement itself tracked closely with adherence: 55 of 83, 66.26%, of patients currently in therapy were in the high-adherence group, and 61 of 106, 57.54%, of those taking medication also showed higher adherence (P < .001 for both).
- The study used an evenly split comparison of 65 treatment-compliant and 65 treatment-noncompliant participants, which makes the observed differences in belief domains clinically easier to interpret at the point of care.
- Perceived benefit remained significant in multivariable testing (β=0.295, P =.001), suggesting that clinicians may gain more by directly testing whether patients expect therapy or medication to help than by focusing on illness seriousness alone.
- Perceived barriers showed a significant inverse association with adherence in both group comparisons (P=.007) and regression analysis (β=−1.633, P =.015), supporting routine screening for practical and psychosocial obstacles during follow-up.
- Severity- and risk-based messaging may have limited value for this population in isolation, because perceived severity and perceived susceptibility were not associated with compliance (P=1.0 for both), and cues to action were also nonsignificant (P=.216).